Stent Restenosis Clinical Trial
— BIOFLEX-COFOfficial title:
Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions
Verified date | February 2020 |
Source | Medical University of Vienna |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of the BIOFLEX-COF trial is to investigate differences in formation of intimal
hyperplasia at one and two years after implantation of nitinol-stents with high vs. low COF
in de-novo femoropopliteal occlusive lesions in patients with symptomatic peripheral arterial
disease.
The BIOFLEX-COF trial is a prospective, randomized controlled trial. 80 subjects will be
enrolled and randomly assigned to either a high COF group (LifeStent Vascular Stent) or low
COF group (Pulsar).
Status | Active, not recruiting |
Enrollment | 86 |
Est. completion date | December 31, 2020 |
Est. primary completion date | July 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patient related: 1. Subject (or their legal guardian) has read, understood and provided written informed consent, which has been reviewed and approved by the Institutional Review Board. 2. At least 18 years of age. 3. Male, infertile female or female participants of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7-days prior to study procedure. 4. Projected life expectancy of greater than two years. 5. The ability to comply with protocol follow-up requirements and required testing. Clinical: 1. Lifestyle-limiting claudication or CLI (meeting angiographic entry criteria) affecting a lower extremity (Rutherford stages 2-5). Patients with Rutherford stage 2 are only eligible after unsuccessful conventional and/or medicamentous therapy. 2. Resting ankle-brachial index (ABI) = 0.8 in the study limb. 3. Inflow lesion - if present - has been treated successfully (inflow treatment in same procedure permissible) Angiographic and Lesion Requirements (assessed intraoperatively): 1. TASC A-D lesions from stenoses /occlusions = 35cm. 2. Popliteal artery is patent 5 cm proximal to the radiographic knee joint line. 3. Reference diameter of 4.0 - 7.0 mm in proximal and distal treatment segments within the SFA. 4. Patent SFA orifice (the proximal 5 mm after femoral bifurcation). 5. At least one patent (<50% stenotic) inflow vessel present, proven angiographically. Study eligibility is given when inflow lesion has been treated successfully (inflow treatment in same procedure permissible). Successful treatment of inflow lesion is defined as <50% stenosis without death or severe vascular complication. 6. At least one patent (<50% stenotic)tibial artery runoff to the ankle present, proven angiographically. Study eligibility is given when runoff vessel lesion has been treated successfully (inflow treatment in same procedure permissible). Successful treatment of inflow lesion is defined as <50% stenosis without death or severe vascular complication.Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel. Exclusion Criteria: 1. Pregnant and/or breast-feeding women. 2. Lesion length > 35 cm. 3. Flow-limiting occlusive disease of inflow and / or outflow arteries that cannot be treated sufficiently. 4. Previous stenting or femoral bypass surgery in the target vessel. 5. Clinical relevant aneurysmatic disease of the abdominal aorta, ipsilateral femoral arteries or arteries of the knee. 6. Rutherford stage 0, 1 or 6 7. Non-atherosclerotic disease resulting in occlusion (e.g., embolism, Buerger's disease, vasculitis). 8. Septicaemia. 9. Ischemic stroke within the last three months. 10. Any previously known coagulation disorder, including hypercoagulability 11. Morbid obesity or operative scarring that precludes percutaneous approach (physician's discretion). 12. Contraindication to anticoagulation or antiplatelet therapy. 13. Known allergy to medication or contrast media used in this trial, if pre-treatment is not possible (physician's discretion). 14. Known allergies to stent components (especially Nickel). 15. Severe calcification of the target lesion. 16. Current participation in another clinical research trial, that has not reached its primary endpoint. 17. The patient is institutionalized based on a legal verdict. |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Vienna | Vienna |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna |
Austria,
Brodmann M. Prime time for drug eluting balloons in SFA interventions? J Cardiovasc Surg (Torino). 2014 Aug;55(4):461-4. Epub 2014 Jun 18. Review. — View Citation
Cho H, Nango M, Sakai Y, Sohgawa E, Kageyama K, Hamamoto S, Kitayama T, Yamamoto A, Miki Y. Neointimal hyperplasia after stent placement across size-discrepant vessels in an animal study. Jpn J Radiol. 2014 Jun;32(6):340-6. doi: 10.1007/s11604-014-0311-3. Epub 2014 Apr 9. — View Citation
Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011 Oct 1;4(5):495-504. doi: 10.1161/CIRCINTERVENTIONS.111.962324. Epub 2011 Sep 27. — View Citation
Deloose K, Lauwers K, Callaert J, Maene L, Keirse K, Verbist J, Peeters P, Bosiers M. Drug-eluting technologies in femoral artery lesions. J Cardiovasc Surg (Torino). 2013 Apr;54(2):217-24. Review. — View Citation
Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, Koppensteiner R, Minar E, Schillinger M. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1090-5. doi: 10.1002/ccd.22128. — View Citation
Freeman JW, Snowhill PB, Nosher JL. A link between stent radial forces and vascular wall remodeling: the discovery of an optimal stent radial force for minimal vessel restenosis. Connect Tissue Res. 2010 Aug;51(4):314-26. doi: 10.3109/03008200903329771. — View Citation
Gouëffic Y, Kaladji A, Guyomarch B, Montagne C, Fairier D, Gestin S, Riche VP, Vent PA, Chaillou P, Costargent A, Patra P. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial. Trials. 2014 Oct 30;15:423. doi: 10.1186/1745-6215-15-423. — View Citation
Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Comittee(.). Ann Vasc Dis. 2015;8(4):343-57. doi: 10.3400/avd.tasc.15-01000. Epub 2015 Oct 23. — View Citation
Johnston CR, Lee K, Flewitt J, Moore R, Dobson GM, Thornton GM. The mechanical properties of endovascular stents: an in vitro assessment. Cardiovasc Eng. 2010 Sep;10(3):128-35. doi: 10.1007/s10558-010-9097-9. — View Citation
Kirsch EC, Khangure MS, Morling P, York TJ, McAuliffe W. Oversizing of self-expanding stents: influence on the development of neointimal hyperplasia of the carotid artery in a canine model. AJNR Am J Neuroradiol. 2002 Jan;23(1):121-7. — View Citation
Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tübler T, Zeller T. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007 Jul 17;116(3):285-92. Epub 2007 Jun 25. — View Citation
Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Beschorner U, Ristl R, Schoder M. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol. 2015 Feb;38(1):25-32. doi: 10.1007/s00270-014-1024-9. Epub 2014 Dec 5. Erratum in: Cardiovasc Intervent Radiol. 2015 Jun;38(3):779-80. — View Citation
Minar E, Schillinger M. Innovative technologies for SFA occlusions: drug coated balloons in SFA lesions. J Cardiovasc Surg (Torino). 2012 Aug;53(4):481-6. Review. — View Citation
Rastan A, Krankenberg H, Baumgartner I, Blessing E, Müller-Hülsbeck S, Pilger E, Scheinert D, Lammer J, Beschorner U, Noory E, Neumann FJ, Zeller T. Stent placement vs. balloon angioplasty for popliteal artery treatment: two-year results of a prospective, multicenter, randomized trial. J Endovasc Ther. 2015 Feb;22(1):22-7. doi: 10.1177/1526602814564386. — View Citation
Saguner AM, Traupe T, Räber L, Hess N, Banz Y, Saguner AR, Diehm N, Hess OM. Oversizing and restenosis with self-expanding stents in iliofemoral arteries. Cardiovasc Intervent Radiol. 2012 Aug;35(4):906-13. doi: 10.1007/s00270-011-0275-y. Epub 2011 Oct 18. — View Citation
Saxon RR, Chervu A, Jones PA, Bajwa TK, Gable DR, Soukas PA, Begg RJ, Adams JG, Ansel GM, Schneider DB, Eichler CM, Rush MJ. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol. 2013 Feb;24(2):165-73; quiz 174. doi: 10.1016/j.jvir.2012.10.004. Epub 2013 Jan 28. — View Citation
Saxon RR, Dake MD, Volgelzang RL, Katzen BT, Becker GJ. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008 Jun;19(6):823-32. doi: 10.1016/j.jvir.2008.02.008. Epub 2008 Apr 10. — View Citation
Schmidt W, Wissgott C, Andresen R, Behrens P, Schmitz KP. Performance characteristics of modern self-expanding nitinol stents indicated for SFA. Rofo. 2011 Sep;183(9):818-25. doi: 10.1055/s-0031-1273445. Epub 2011 Jul 12. — View Citation
Vorwerk D, Redha F, Neuerburg J, Clerc C, Günther RW. Neointima formation following arterial placement of self-expanding stents of different radial force: experimental results. Cardiovasc Intervent Radiol. 1994 Jan-Feb;17(1):27-32. — View Citation
Zhao HQ, Nikanorov A, Virmani R, Jones R, Pacheco E, Schwartz LB. Late stent expansion and neointimal proliferation of oversized Nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. 2009 Jul;32(4):720-6. doi: 10.1007/s00270-009-9601-z. Epub 2009 May 30. — View Citation
* Note: There are 20 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Amount of in-stent restenosis | Mean amount of in-stent restenosis in percent along the stent axis at one and two years post-procedure. | one and two years post-procedure | |
Secondary | Adverse Events ISO 14155:2011 | Adverse Events ISO 14155:2011 | within two years post-procedure | |
Secondary | Target lesion revascularisation (TLR) | In patients with TLR the amount of in-stent restenosis will be assessed at the time of TLR. | within two years post-procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06112028 -
Clinical Study of Tongxinluo Capsule in Preventing and Treating Restenosis After Intracranial and External Arterial Stenting
|
Phase 4 | |
Completed |
NCT05591365 -
Exercise Training in Coronary Artery Disease Patients After Stenting
|
N/A | |
Completed |
NCT05315193 -
Effect of Exercise Training in Coronary Artery Disease Patients After Stenting
|
N/A | |
Recruiting |
NCT05346068 -
The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial
|
N/A | |
Active, not recruiting |
NCT03349385 -
Registry of Secondary Revascularization
|
||
Recruiting |
NCT04325867 -
Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19
|
N/A | |
Recruiting |
NCT05244629 -
Copenhagen Mesenteric Stent Study - A Randomized Trial of Stent Versus Covered Stent Treatment for Chronic Mesenteric Ischemia
|
N/A | |
Completed |
NCT03544294 -
veRy Thin Stents for Patients With Left mAIn or bifurcatioN in Real Life: the RAIN a Multicenter Study
|
||
Completed |
NCT05217459 -
The Efficacy and Safety of Intracranial Self-expanding DES in Symptomatic Intracranial Atherosclerotic Disease
|
N/A | |
Recruiting |
NCT05205148 -
Ultrathin DES in Complex PCI Scenarios: the ULTRA a Multicenter Study
|
||
Not yet recruiting |
NCT03375528 -
Matrix Metalloproteinases Expression in the Neointimal Hyperplasia Induced by Drug Eluting Stent (DES) Implantation
|
N/A | |
Completed |
NCT06276114 -
IVL vs ELCA for Stent Underexpantsion (IVL-ELCA DRAGON)
|